IntAct European Bioinformatics Institute IntAct intact http://www.ebi.ac.uk/ http://www.ebi.ac.uk/intact/query/${ac} EBI-[0-9]+|IA:[0-9]+ INTerAction database (IntAct) provides an open source database and toolkit for the storage, presentation and analysis of molecular interactions. http://www.ebi.ac.uk/intact European Bioinformatics Institute; Wellcome Trust Genome Campus; Hinxton, Cambridge; CB10 1SD; United Kingdom http://www.ebi.ac.uk/intact/ MALAT1/miR-101-3p/MCL1 axis mediates cisplatin resistance in lung cancer. MALAT1/miR-101-3p/MCL1 axis mediates cisplatin resistance in lung cancer. Oncotarget 2018 imex curation Wang H., Wang L., Zhang G., Lu C., Chu H., Yang R., Zhao G., Wang H., Wang L., Zhang G., Lu C., Chu H., Yang R., Zhao G. gjzhangzzu@126.com 09-May-2019: Contacted by IntAct-Help. Only protein-protein interactions imex curation human-h1299 Homo sapiens lung lymph node carcinoma h1299 Human lung lymph node carcinoma p53 null. These cells have also been reported to secrete the peptide hormone neuromedin B (NMB), but not gastrin releasing peptide (GRP). Also known as NCI H1299 or CRL-5803. http://www.lgcpromochem.com/atcc/ ATCC number: CRL-5803. ATCC number of the cell line is CRL-5803. mirna interference luciferase assay miRNA interference luciferase reporter assay miRNA interference luciferase assay tag luciferase tag visualisation by luciferase assay tag luciferase Wang H., Wang L., Zhang G., Lu C., Chu H., Yang R., Zhao G., Wang H., Wang L., Zhang G., Lu C., Chu H., Yang R., Zhao G. gjzhangzzu@126.com Accepted 2018-JUN-14 AT 09:39 BST AT 09:39 BST by ORCHARD Oncotarget 2018 IMEx imex curation MALAT1/miR-101-3p/MCL1 axis mediates cisplatin resistance in lung cancer. MALAT1/miR-101-3p/MCL1 axis mediates cisplatin resistance in lung cancer. Oncotarget 2018 imex curation Wang H., Wang L., Zhang G., Lu C., Chu H., Yang R., Zhao G., Wang H., Wang L., Zhang G., Lu C., Chu H., Yang R., Zhao G. gjzhangzzu@126.com 09-May-2019: Contacted by IntAct-Help. Only protein-protein interactions imex curation human-h1299 Homo sapiens lung lymph node carcinoma h1299 Human lung lymph node carcinoma p53 null. These cells have also been reported to secrete the peptide hormone neuromedin B (NMB), but not gastrin releasing peptide (GRP). Also known as NCI H1299 or CRL-5803. http://www.lgcpromochem.com/atcc/ ATCC number: CRL-5803. ATCC number of the cell line is CRL-5803. rna-ip rna immunoprecipitation rna-ip qrt-pcr quantitative reverse transcription pcr QRT-PCR Wang H., Wang L., Zhang G., Lu C., Chu H., Yang R., Zhao G., Wang H., Wang L., Zhang G., Lu C., Chu H., Yang R., Zhao G. gjzhangzzu@126.com Accepted 2018-JUN-14 AT 09:39 BST AT 09:39 BST by ORCHARD Oncotarget 2018 IMEx imex curation MALAT1/miR-101-3p/MCL1 axis mediates cisplatin resistance in lung cancer. MALAT1/miR-101-3p/MCL1 axis mediates cisplatin resistance in lung cancer. Oncotarget 2018 imex curation Wang H., Wang L., Zhang G., Lu C., Chu H., Yang R., Zhao G., Wang H., Wang L., Zhang G., Lu C., Chu H., Yang R., Zhao G. gjzhangzzu@126.com 09-May-2019: Contacted by IntAct-Help. Only protein-protein interactions imex curation human-a_549 Homo sapiens Caucasian lung carcinoma cell line a_549 Human Caucasian lung carcinoma mirna interference luciferase assay miRNA interference luciferase reporter assay miRNA interference luciferase assay tag luciferase tag visualisation by luciferase assay tag luciferase Wang H., Wang L., Zhang G., Lu C., Chu H., Yang R., Zhao G., Wang H., Wang L., Zhang G., Lu C., Chu H., Yang R., Zhao G. gjzhangzzu@126.com Accepted 2018-JUN-14 AT 09:39 BST AT 09:39 BST by ORCHARD Oncotarget 2018 imex curation MALAT1/miR-101-3p/MCL1 axis mediates cisplatin resistance in lung cancer. MALAT1/miR-101-3p/MCL1 axis mediates cisplatin resistance in lung cancer. Oncotarget 2018 imex curation Wang H., Wang L., Zhang G., Lu C., Chu H., Yang R., Zhao G., Wang H., Wang L., Zhang G., Lu C., Chu H., Yang R., Zhao G. gjzhangzzu@126.com 09-May-2019: Contacted by IntAct-Help. Only protein-protein interactions imex curation human Homo sapiens Human mirna interference luciferase assay miRNA interference luciferase reporter assay miRNA interference luciferase assay tag luciferase tag visualisation by luciferase assay tag luciferase Wang H., Wang L., Zhang G., Lu C., Chu H., Yang R., Zhao G., Wang H., Wang L., Zhang G., Lu C., Chu H., Yang R., Zhao G. Host organism: human because it is not specified if it is in H1299 or A541 gjzhangzzu@126.com Accepted 2018-JUN-14 AT 09:39 BST AT 09:39 BST by ORCHARD Oncotarget 2018 imex curation MALAT1/miR-101-3p/MCL1 axis mediates cisplatin resistance in lung cancer. MALAT1/miR-101-3p/MCL1 axis mediates cisplatin resistance in lung cancer. Oncotarget 2018 imex curation Wang H., Wang L., Zhang G., Lu C., Chu H., Yang R., Zhao G., Wang H., Wang L., Zhang G., Lu C., Chu H., Yang R., Zhao G. gjzhangzzu@126.com 09-May-2019: Contacted by IntAct-Help. Only protein-protein interactions imex curation human-a_549 Homo sapiens Caucasian lung carcinoma cell line a_549 Human Caucasian lung carcinoma rna-ip rna immunoprecipitation rna-ip qrt-pcr quantitative reverse transcription pcr QRT-PCR Wang H., Wang L., Zhang G., Lu C., Chu H., Yang R., Zhao G., Wang H., Wang L., Zhang G., Lu C., Chu H., Yang R., Zhao G. gjzhangzzu@126.com Accepted 2018-JUN-14 AT 09:39 BST AT 09:39 BST by ORCHARD Oncotarget 2018 IMEx imex curation mrna_mcl1 myeloid cell leukemia 1 mrna messenger rna mRNA mrna human Homo sapiens Human GCGCAACCCTCCGGAAGCTGCCGCCCCTTTCCCCTTTTATGGGAATACTTTTTTTAAAAAAAAAGAGTTCGCTGGCGCCACCCCGTAGGACTGGCCGCCCTAAAACCGTGATAAAGGAGCTGCTCGCCACTTCTCACTTCCGCTTCCTTCCAGTAAGGAGTCGGGGTCTTCCCCAGTTTTCTCAGCCAGGCGGCGGCGGCGACTGGCAATGTTTGGCCTCAAAAGAAACGCGGTAATCGGACTCAACCTCTACTGTGGGGGGGCCGGCTTGGGGGCCGGCAGCGGCGGCGCCACCCGCCCGGGAGGGCGACTTTTGGCTACGGAGAAGGAGGCCTCGGCCCGGCGAGAGATAGGGGGAGGGGAGGCCGGCGCGGTGATTGGCGGAAGCGCCGGCGCAAGCCCCCCGTCCACCCTCACGCCAGACTCCCGGAGGGTCGCGCGGCCGCCGCCCATTGGCGCCGAGGTCCCCGACGTCACCGCGACCCCCGCGAGGCTGCTTTTCTTCGCGCCCACCCGCCGCGCGGCGCCGCTTGAGGAGATGGAAGCCCCGGCCGCTGACGCCATCATGTCGCCCGAAGAGGAGCTGGACGGGTACGAGCCGGAGCCTCTCGGGAAGCGGCCGGCTGTCCTGCCGCTGCTGGAGTTGGTCGGGGAATCTGGTAATAACACCAGTACGGACGGGTCACTACCCTCGACGCCGCCGCCAGCAGAGGAGGAGGAGGACGAGTTGTACCGGCAGTCGCTGGAGATTATCTCTCGGTACCTTCGGGAGCAGGCCACCGGCGCCAAGGACACAAAGCCAATGGGCAGGTCTGGGGCCACCAGCAGGAAGGCGCTGGAGACCTTACGACGGGTTGGGGATGGCGTGCAGCGCAACCACGAGACGGCCTTCCAAGGCATGCTTCGGAAACTGGACATCAAAAACGAAGACGATGTGAAATCGTTGTCTCGAGTGATGATCCATGTTTTCAGCGACGGCGTAACAAACTGGGGCAGGATTGTGACTCTCATTTCTTTTGGTGCCTTTGTGGCTAAACACTTGAAGACCATAAACCAAGAAAGCTGCATCGAACCATTAGCAGAAAGTATCACAGACGTTCTCGTAAGGACAAAACGGGACTGGCTAGTTAAACAAAGAGGCTGGGATGGGTTTGTGGAGTTCTTCCATGTAGAGGACCTAGAAGGTGGCATCAGGAATGTGCTGCTGGCTTTTGCAGGTGTTGCTGGAGTAGGAGCTGGTTTGGCATATCTAATAAGATAGCCTTACTGTAAGTGCAATAGTTGACTTTTAACCAACCACCACCACCACCAAAACCAGTTTATGCAGTTGGACTCCAAGCTGTAACTTCCTAGAGTTGCACCCTAGCAACCTAGCCAGAAAAGCAAGTGGCAAGAGGATTATGGCTAACAAGAATAAATACATGGGAAGAGTGCTCCCCATTGATTGAAGAGTCACTGTCTGAAAGAAGCAAAGTTCAGTTTCAGCAACAAACAAACTTTGTTTGGGAAGCTATGGAGGAGGACTTTTAGATTTAGTGAAGATGGTAGGGTGGAAAGACTTAATTTCCTTGTTGAGAACAGGAAAGTGGCCAGTAGCCAGGCAAGTCATAGAATTGATTACCCGCCGAATTCATTAATTTACTGTAGTGTTAAGAGAAGCACTAAGAATGCCAGTGACCTGTGTAAAAGTTACAAGTAATAGAACTATGACTGTAAGCCTCAGTACTGTACAAGGGAAGCTTTTCCTCTCTCTAATTAGCTTTCCCAGTATACTTCTTAGAAAGTCCAAGTGTTCAGGACTTTTATACCTGTTATACTTTGGCTTGGTTTCCATGATTCTTACTTTATTAGCCTAGTTTATCACCAATAATACTTGACGGAAGGCTCAGTAATTAGTTATGAATATGGATATCCTCAATTCTTAAGACAGCTTGTAAATGTATTTGTAAAAATTGTATATATTTTTACAGAAAGTCTATTTCTTTGAAACGAAGGAAGTATCGAATTTACATTAGTTTTTTTCATACCCTTTTGAACTTTGCAACTTCCGTAATTAGGAACCTGTTTCTTACAGCTTTTCTATGCTAAACTTTGTTCTGTTCAGTTCTAGAGTGTATACAGAACGAATTGATGTGTAACTGTATGCAGACTGGTTGTAGTGGAACAAATCTGATAACTATGCAGGTTTAAATTTTCTTATCTGATTTTGGTAAGTATTCCTTAGATAGGTTTTTCTTTGAAAACCTGGGATTGAGAGGTTGATGAATGGAAATTCTTTCACTTCATTATATGCAAGTTTTCAATAATTAGGTCTAAGTGGAGTTTTAAGGTTACTGATGACTTACAAATAATGGGCTCTGATTGGGCAATACTCATTTGAGTTCCTTCCATTTGACCTAATTTAACTGGTGAAATTTAAAGTGAATTCATGGGCTCATCTTTAAAGCTTTTACTAAAAGATTTTCAGCTGAATGGAACTCATTAGCTGTGTGCATATAAAAAGATCACATCAGGTGGATGGAGAGACATTTGATCCCTTGTTTGCTTAATAAATTATAAAATGATGGCTTGGAAAAGCAGGCTAGTCTAACCATGGTGCTATTATTAGGCTTGCTTGTTACACACACAGGTCTAAGCCTAGTATGTCAATAAAGCAAATACTTACTGTTTTGTTTCTATTAATGATTCCCAAACCTTGTTGCAAGTTTTTGCATTGGCATCTTTGGATTTCAGTCTTGATGTTTGTTCTATCAGACTTAACCTTTTATTTCCTGTCCTTCCTTGAAATTGCTGATTGTTCTGCTCCCTCTACAGATATTTATATCAATTCCTACAGCTTTCCCCTGCCATCCCTGAACTCTTTCTAGCCCTTTTAGATTTTGGCACTGTGAAACCCCTGCTGGAAACCTGAGTGACCCTCCCTCCCCACCAAGAGTCCACAGACCTTTCATCTTTCACGAACTTGATCCTGTTAGCAGGTGGTAATACCATGGGTGCTGTGACACTAACAGTCATTGAGAGGTGGGAGGAAGTCCCTTTTCCTTGGACTGGTATCTTTTCAACTATTGTTTTATCCTGTCTTTGGGGGCAATGTGTCAAAAGTCCCCTCAGGAATTTTCAGAGGAAAGAACATTTTATGAGGCTTTCTCTAAAGTTTCCTTTGTATAGGAGTATGCTCACTTAAATTTACAGAAAGAGGTGAGCTGTGTTAAACCTCAGAGTTTAAAAGCTACTGATAAACTGAAGAAAGTGTCTATATTGGAACTAGGGTCATTTGAAAGCTTCAGTCTCGGAACATGACCTTTAGTCTGTGGACTCCATTTAAAAATAGGTATGAATAAGATGACTAAGAATGTAATGGGGAAGAACTGCCCTGCCTGCCCATCTCAGAGCCATAAGGTCATCTTTGCTAGAGCTATTTTTACCTATGTATTTATCGTTCTTGATCATAAGCCGCTTATTTATATCATGTATCTCTAAGGACCTAAAAGCACTTTATGTAGTTTTTAATTAATCTTAAGATCTGGTTACGGTAACTAAAAAAGCCTGTCTGCCAAATCCAGTGGAAACAAGTGCATAGATGTGAATTGGTTTTTAGGGGCCCCACTTCCCAATTCATTAGGTATGACTGTGGAAATACAGACAAGGATCTTAGTTGATATTTTGGGCTTGGGGCAGTGAGGGCTTAGGACACCCCAAGTGGTTTGGGAAAGGAGGAGGGGAGTGGTGGGTTTATAGGGGGAGGAGGAGGCAGGTGGTCTAAGTGCTGACTGGCTACGTAGTTCGGGCAAATCCTCCAAAAGGGAAAGGGAGGATTTGCTTAGAAGGATGGCGCTCCCAGTGACTACTTTTTGACTTCTGTTTGTCTTACGCTTCTCTCAGGGAAAAACATGCAGTCCTCTAGTGTTTCATGTACATTCTGTGGGGGGTGAACACCTTGGTTCTGGTTAAACAGCTGTACTTTTGATAGCTGTGCCAGGAAGGGTTAGGACCAACTACAAATTAATGTTGGTTGTCAAATGTAGTGTGTTTCCCTAACTTTCTGTTTTTCCTGAGAAAAAAAAATAAATCTTTTATTCAAATACAGGGAAAAAAAAAAAAAAAAAA ago2_human Protein argonaute-2 AGO2 Argonaute RISC catalytic component 2 EIF2C2 Eukaryotic translation initiation factor 2C 2 PAZ Piwi domain protein Protein slicer protein protein human Homo sapiens Human MYSGAGPALAPPAPPPPIQGYAFKPPPRPDFGTSGRTIKLQANFFEMDIPKIDIYHYELDIKPEKCPRRVNREIVEHMVQHFKTQIFGDRKPVFDGRKNLYTAMPLPIGRDKVELEVTLPGEGKDRIFKVSIKWVSCVSLQALHDALSGRLPSVPFETIQALDVVMRHLPSMRYTPVGRSFFTASEGCSNPLGGGREVWFGFHQSVRPSLWKMMLNIDVSATAFYKAQPVIEFVCEVLDFKSIEEQQKPLTDSQRVKFTKEIKGLKVEITHCGQMKRKYRVCNVTRRPASHQTFPLQQESGQTVECTVAQYFKDRHKLVLRYPHLPCLQVGQEQKHTYLPLEVCNIVAGQRCIKKLTDNQTSTMIRATARSAPDRQEEISKLMRSASFNTDPYVREFGIMVKDEMTDVTGRVLQPPSILYGGRNKAIATPVQGVWDMRNKQFHTGIEIKVWAIACFAPQRQCTEVHLKSFTEQLRKISRDAGMPIQGQPCFCKYAQGADSVEPMFRHLKNTYAGLQLVVVILPGKTPVYAEVKRVGDTVLGMATQCVQMKNVQRTTPQTLSNLCLKINVKLGGVNNILLPQGRPPVFQQPVIFLGADVTHPPAGDGKKPSIAAVVGSMDAHPNRYCATVRVQQHRQEIIQDLAAMVRELLIQFYKSTRFKPTRIIFYRDGVSEGQFQQVLHHELLAIREACIKLEKDYQPGITFIVVQKRHHTRLFCTDKNERVGKSGNIPAGTTVDTKITHPTEFDFYLCSHAGIQGTSRPSHYHVLWDDNRFSSDELQILTYQLCHTYVRCTRSVSIPAPAYYAHLVAFRARYHLVDKEHDSAEGSHTSGQSNGRDHQALAKAVQVHQDTLRTMYFA DIP protein Q9UKV8 original sequence version: 1(def) DIP protein Q9UKV8 original sequence version: 44 DIP protein Q9UKV8 original sequence version: 60 DIP protein Q9UKV8 original sequence version: 62 DIP protein Q9UKV8 original sequence version: 89 DIP protein Q9UKV8 original sequence version: 85 DIP protein Q9UKV8 original sequence version: 87 DIP protein Q9UKV8 original sequence version: 99 DIP protein Q9UKV8 original sequence version: 117 DIP protein Q9UKV8-1 original sequence version: 117 DIP protein Q9UKV8 original sequence version: 145 DIP protein Q9UKV8 original sequence version: 108 5C8552C43FC81345 lncrn_malat1 human metastasis associated lung adenocarcinoma transcript 1 lncrna long non-coding ribonucleic acid lncRNA long non coding RNA long non coding ribonucleic acid long non-coding RNA lncrna human Homo sapiens Human CGCAGCCUGCAGCCCGAGACUUCUGUAAAGGACUGGGGCCCCGCAACUGGCCUCUCCUGCCCUCUUAAGCGCAGCGCCAUUUUAGCAACGCAGAAGCCCGGCGCCGGGAAGCCUCAGCUCGCCUGAAGGCAGGUCCCCUCUGACGCCUCCGGGAGCCCAGGUUUCCCAGAGUCCUUGGGACGCAGCGACGAGUUGUGCUGCUAUCUUAGCUGUCCUUAUAGGCUGGCCAUUCCAGGUGGUGGUAUUUAGAUAAAACCACUCAAACUCUGCAGUUUGGUCUUGGGGUUUGGAGGAAAGCUUUUAUUUUUCUUCCUGCUCCGGUUCAGAAGGUCUGAAGCUCAUACCUAACCAGGCAUAACACAGAAUCUGCAAAACAAAAACCCCUAAAAAAGCAGACCCAGAGCAGUGUAAACACUUCUGGGUGUGUCCCUGACUGGCUGCCCAAGGUCUCUGUGUCUUCGGAGACAAAGCCAUUCGCUUAGUUGGUCUACUUUAAAAGGCCACUUGAACUCGCUUUCCAUGGCGAUUUGCCUUGUGAGCACUUUCAGGAGAGCCUGGAAGCUGAAAAACGGUAGAAAAAUUUCCGUGCGGGCCGUGGGGGGCUGGCGGCAACUGGGGGGCCGCAGAUCAGAGUGGGCCACUGGCAGCCAACGGCCCCCGGGGCUCAGGCGGGGAGCAGCUCUGUGGUGUGGGAUUGAGGCGUUUUCCAAGAGUGGGUUUUCACGUUUCUAAGAUUUCCCAAGCAGACAGCCCGUGCUGCUCCGAUUUCUCGAACAAAAAAGCAAAACGUGUGGCUGUCUUGGGAGCAAGUCGCAGGACUGCAAGCAGUUGGGGGAGAAAGUCCGCCAUUUUGCCACUUCUCAACCGUCCCUGCAAGGCUGGGGCUCAGUUGCGUAAUGGAAAGUAAAGCCCUGAACUAUCACACUUUAAUCUUCCUUCAAAAGGUGGUAAACUAUACCUACUGUCCCUCAAGAGAACACAAGAAGUGCUUUAAGAGGUAUUUUAAAAGUUCCGGGGGUUUUGUGAGGUGUUUGAUGACCCGUUUAAAAUAUGAUUUCCAUGUUUCUUUUGUCUAAAGUUUGCAGCUCAAAUCUUUCCACACGCUAGUAAUUUAAGUAUUUCUGCAUGUGUAGUUUGCAUUCAAGUUCCAUAAGCUGUUAAGAAAAAUCUAGAAAAGUAAAACUAGAACCUAUUUUUAACCGAAGAACUACUUUUUGCCUCCCUCACAAAGGCGGCGGAAGGUGAUCGAAUUCCGGUGAUGCGAGUUGUUCUCCGUCUAUAAAUACGCCUCGCCCGAGCUGUGCGGUAGGCAUUGAGGCAGCCAGCGCAGGGGCUUCUGCUGAGGGGGCAGGCGGAGCUUGAGGAAACCGCAGAUAAGUUUUUUUCUCUUUGAAAGAUAGAGAUUAAUACAACUACUUAAAAAAUAUAGUCAAUAGGUUACUAAGAUAUUGCUUAGCGUUAAGUUUUUAACGUAAUUUUAAUAGCUUAAGAUUUUAAGAGAAAAUAUGAAGACUUAGAAGAGUAGCAUGAGGAAGGAAAAGAUAAAAGGUUUCUAAAACAUGACGGAGGUUGAGAUGAAGCUUCUUCAUGGAGUAAAAAAUGUAUUUAAAAGAAAAUUGAGAGAAAGGACUACAGAGCCCCGAAUUAAUACCAAUAGAAGGGCAAUGCUUUUAGAUUAAAAUGAAGGUGACUUAAACAGCUUAAAGUUUAGUUUAAAAGUUGUAGGUGAUUAAAAUAAUUUGAAGGCGAUCUUUUAAAAAGAGAUUAAACCGAAGGUGAUUAAAAGACCUUGAAAUCCAUGACGCAGGGAGAAUUGCGUCAUUUAAAGCCUAGUUAACGCAUUUACUAAACGCAGACGAAAAUGGAAAGAUUAAUUGGGAGUGGUAGGAUGAAACAAUUUGGAGAAGAUAGAAGUUUGAAGUGGAAAACUGGAAGACAGAAGUACGGGAAGGCGAAGAAAAGAAUAGAGAAGAUAGGGAAAUUAGAAGAUAAAAACAUACUUUUAGAAGAAAAAAGAUAAAUUUAAACCUGAAAAGUAGGAAGCAGAAGAAAAAAGACAAGCUAGGAAACAAAAAGCUAAGGGCAAAAUGUACAAACUUAGAAGAAAAUUGGAAGAUAGAAACAAGAUAGAAAAUGAAAAUAUUGUCAAGAGUUUCAGAUAGAAAAUGAAAAACAAGCUAAGACAAGUAUUGGAGAAGUAUAGAAGAUAGAAAAAUAUAAAGCCAAAAAUUGGAUAAAAUAGCACUGAAAAAAUGAGGAAAUUAUUGGUAACCAAUUUAUUUUAAAAGCCCAUCAAUUUAAUUUCUGGUGGUGCAGAAGUUAGAAGGUAAAGCUUGAGAAGAUGAGGGUGUUUACGUAGACCAGAACCAAUUUAGAAGAAUACUUGAAGCUAGAAGGGGAAGUUGGUUAAAAAUCACAUCAAAAAGCUACUAAAAGGACUGGUGUAAUUUAAAAAAAACUAAGGCAGAAGGCUUUUGGAAGAGUUAGAAGAAUUUGGAAGGCCUUAAAUAUAGUAGCUUAGUUUGAAAAAUGUGAAGGACUUUCGUAACGGAAGUAAUUCAAGAUCAAGAGUAAUUACCAACUUAAUGUUUUUGCAUUGGACUUUGAGUUAAGAUUAUUUUUUAAAUCCUGAGGACUAGCAUUAAUUGACAGCUGACCCAGGUGCUACACAGAAGUGGAUUCAGUGAAUCUAGGAAGACAGCAGCAGACAGGAUUCCAGGAACCAGUGUUUGAUGAAGCUAGGACUGAGGAGCAAGCGAGCAAGCAGCAGUUCGUGGUGAAGAUAGGAAAAGAGUCCAGGAGCCAGUGCGAUUUGGUGAAGGAAGCUAGGAAGAAGGAAGGAGCGCUAACGAUUUGGUGGUGAAGCUAGGAAAAAGGAUUCCAGGAAGGAGCGAGUGCAAUUUGGUGAUGAAGGUAGCAGGCGGCUUGGCUUGGCAACCACACGGAGGAGGCGAGCAGGCGUUGUGCGUAGAGGAUCCUAGACCAGCAUGCCAGUGUGCCAAGGCCACAGGGAAAGCGAGUGGUUGGUAAAAAUCCGUGAGGUCGGCAAUAUGUUGUUUUUCUGGAACUUACUUAUGGUAACCUUUUAUUUAUUUUCUAAUAUAAUGGGGGAGUUUCGUACUGAGGUGUAAAGGGAUUUAUAUGGGGACGUAGGCCGAUUUCCGGGUGUUGUAGGUUUCUCUUUUUCAGGCUUAUACUCAUGAAUCUUGUCUGAAGCUUUUGAGGGCAGACUGCCAAGUCCUGGAGAAAUAGUAGAUGGCAAGUUUGUGGGUUUUUUUUUUUUACACGAAUUUGAGGAAAACCAAAUGAAUUUGAUAGCCAAAUUGAGACAAUUUCAGCAAAUCUGUAAGCAGUUUGUAUGUUUAGUUGGGGUAAUGAAGUAUUUCAGUUUUGUGAAUAGAUGACCUGUUUUUACUUCCUCACCCUGAAUUCGUUUUGUAAAUGUAGAGUUUGGAUGUGUAACUGAGGCGGGGGGGAGUUUUCAGUAUUUUUUUUUGUGGGGGUGGGGGCAAAAUAUGUUUUCAGUUCUUUUUCCCUUAGGUCUGUCUAGAAUCCUAAAGGCAAAUGACUCAAGGUGUAACAGAAAACAAGAAAAUCCAAUAUCAGGAUAAUCAGACCACCACAGGUUUACAGUUUAUAGAAACUAGAGCAGUUCUCACGUUGAGGUCUGUGGAAGAGAUGUCCAUUGGAGAAAUGGCUGGUAGUUACUCUUUUUUCCCCCCACCCCCUUAAUCAGACUUUAAAAGUGCUUAACCCCUUAAACUUGUUAUUUUUUACUUGAAGCAUUUUGGGAUGGUCUUAACAGGGAAGAGAGAGGGUGGGGGAGAAAAUGUUUUUUUCUAAGAUUUUCCACAGAUGCUAUAGUACUAUUGACAAACUGGGUUAGAGAAGGAGUGUACCGCUGUGCUGUUGGCACGAACACCUUCAGGGACUGGAGCUGCUUUUAUCCUUGGAAGAGUAUUCCCAGUUGAAGCUGAAAAGUACAGCACAGUGCAGCUUUGGUUCAUAUUCAGUCAUCUCAGGAGAACUUCAGAAGAGCUUGAGUAGGCCAAAUGUUGAAGUUAAGUUUUCCAAUAAUGUGACUUCUUAAAAGUUUUAUUAAAGGGGAGGGGCAAAUAUUGGCAAUUAGUUGGCAGUGGCCUGUUACGGUUGGGAUUGGUGGGGUGGGUUUAGGUAAUUGUUUAGUUUAUGAUUGCAGAUAAACUCAUGCCAGAGAACUUAAAGUCUUAGAAUGGAAAAAGUAAAGAAAUAUCAACUUCCAAGUUGGCAAGUAACUCCCAAUGAUUUAGUUUUUUUCCCCCCAGUUUGAAUUGGGAAGCUGGGGGAAGUUAAAUAUGAGCCACUGGGUGUACCAGUGCAUUAAUUUGGGCAAGGAAAGUGUCAUAAUUUGAUACUGUAUCUGUUUUCCUUCAAAGUAUAGAGCUUUUGGGGAAGGAAAGUAUUGAACUGGGGGUUGGUCUGGCCUACUGGGCUGACAUUAACUACAAUUAUGGGAAAUGCAAAAGUUGUUUGGAUAUGGUAGUGUGUGGUUCUCUUUUGGAAUUUUUUUCAGGUGAUUUAAUAAUAAUUUAAAACUACUAUAGAAACUGCAGAGCAAAGGAAGUGGCUUAAUGAUCCUGAAGGGAUUUCUUCUGAUGGUAGCUUUUGUAUUAUCAAGUAAGAUUCUAUUUUCAGUUGUGUGUAAGCAAGUUUUUUUUUAGUGUAGGAGAAAUACUUUUCCAUUGUUUAACUGCAAAACAAGAUGUUAAGGUAUGCUUCAAAAAUUUUGUAAAUUGUUUAUUUUAAACUUAUCUGUUUGUAAAUUGUAACUGAUUAAGAAUUGUGAUAGUUCAGCUUGAAUGUCUCUUAGAGGGUGGGCUUUUGUUGAUGAGGGAGGGGAAACUUUUUUUUUUUCUAUAGACUUUUUUCAGAUAACAUCUUCUGAGUCAUAACCAGCCUGGCAGUAUGAUGGCCUAGAUGCAGAGAAAACAGCUCCUUGGUGAAUUGAUAAGUAAAGGCAGAAAAGAUUAUAUGUCAUACCUCCAUUGGGGAAUAAGCAUAACCCUGAGAUUCUUACUACUGAUGAGAACAUUAUCUGCAUAUGCCAAAAAAUUUUAAGCAAAUGAAAGCUACCAAUUUAAAGUUACGGAAUCUACCAUUUUAAAGUUAAUUGCUUGUCAAGCUAUAACCACAAAAAUAAUGAAUUGAUGAGAAAUACAAUGAAGAGGCAAUGUCCAUCUCAAAAUACUGCUUUUACAAAAGCAGAAUAAAAGCGAAAAGAAAUGAAAAUGUUACACUACAUUAAUCCUGGAAUAAAAGAAGCCGAAAUAAAUGAGAGAUGAGUUGGGAUCAAGUGGAUUGAGGAGGCUGUGCUGUGUGCCAAUGUUUCGUUUGCCUCAGACAGGUAUCUCUUCGUUAUCAGAAGAGUUGCUUCAUUUCAUCUGGGAGCAGAAAACAGCAGGCAGCUGUUAACAGAUAAGUUUAACUUGCAUCUGCAGUAUUGCAUGUUAGGGAUAAGUGCUUAUUUUUAAGAGCUGUGGAGUUCUUAAAUAUCAACCAUGGCACUUUCUCCUGACCCCUUCCCUAGGGGAUUUCAGGAUUGAGAAAUUUUUCCAUCGAGCCUUUUUAAAAUUGUAGGACUUGUUCCUGUGGGCUUCAGUGAUGGGAUAGUACACUUCACUCAGAGGCAUUUGCAUCUUUAAAUAAUUUCUUAAAAGCCUCUAAAGUGAUCAGUGCCUUGAUGCCAACUAAGGAAAUUUGUUUAGCAUUGAAUCUCUGAAGGCUCUAUGAAAGGAAUAGCAUGAUGUGCUGUUAGAAUCAGAUGUUACUGCUAAAAUUUACAUGUUGUGAUGUAAAUUGUGUAGAAAACCAUUAAAUCAUUCAAAAUAAUAAACUAUUUUUAUUAGAGAAUGUAUACUUUUAGAAAGCUGUCUCCUUAUUUAAAUAAAAUAGUGUUUGUCUGUAGUUCAGUGUUGGGGCAAUCUUGGGGGGGAUUCUUCUCUAAUCUUUCAGAAACUUUGUCUGCGAACACUCUUUAAUGGACCAGAUCAGGAUUUGAGCGGAAGAACGAAUGUAACUUUAAGGCAGGAAAGACAAAUUUUAUUCUUCAUAAAGUGAUGAGCAUAUAAUAAUUCCAGGCACAUGGCAAUAGAGGCCCUCUAAAUAAGGAAUAAAUAACCUCUUAGACAGGUGGGAGAUUAUGAUCAGAGUAAAAGGUAAUUACACAUUUUAUUUCCAGAAAGUCAGGGGUCUAUAAAUUGACAGUGAUUAGAGUAAUACUUUUUCACAUUUCCAAAGUUUGCAUGUUAACUUUAAAUGCUUACAAUCUUAGAGUGGUAGGCAAUGUUUUACACUAUUGACCUUAUAUAGGGAAGGGAGGGGGUGCCUGUGGGGUUUUAAAGAAUUUUCCUUUGCAGAGGCAUUUCAUCCUUCAUGAAGCCAUUCAGGAUUUUGAAUUGCAUAUGAGUGCUUGGCUCUUCCUUCUGUUCUAGUGAGUGUAUGAGACCUUGCAGUGAGUUUAUCAGCAUACUCAAAAUUUUUUUCCUGGAAUUUGGAGGGAUGGGAGGAGGGGGUGGGGCUUACUUGUUGUAGCUUUUUUUUUUUUUACAGACUUCACAGAGAAUGCAGUUGUCUUGACUUCAGGUCUGUCUGUUCUGUUGGCAAGUAAAUGCAGUACUGUUCUGAUCCCGCUGCUAUUAGAAUGCAUUGUGAAACGACUGGAGUAUGAUUAAAAGUUGUGUUCCCCAAUGCUUGGAGUAGUGAUUGUUGAAGGAAAAAAUCCAGCUGAGUGAUAAAGGCUGAGUGUUGAGGAAAUUUCUGCAGUUUUAAGCAGUCGUAUUUGUGAUUGAAGCUGAGUACAUUUUGCUGGUGUAUUUUUAGGUAAAAUGCUUUUUGUUCAUUUCUGGUGGUGGGAGGGGACUGAAGCCUUUAGUCUUUUCCAGAUGCAACCUUAAAAUCAGUGACAAGAAACAUUCCAAACAAGCAACAGUCUUCAAGAAAUUAAACUGGCAAGUGGAAAUGUUUAAACAGUUCAGUGAUCUUUAGUGCAUUGUUUAUGUGUGGGUUUCUCUCUCCCCUCCCUUGGUCUUAAUUCUUACAUGCAGGAACACUCAGCAGACACACGUAUGCGAAGGGCCAGAGAAGCCAGACCCAGUAAGAAAAAAUAGCCUAUUUACUUUAAAUAAACCAAACAUUCCAUUUUAAAUGUGGGGAUUGGGAACCACUAGUUCUUUCAGAUGGUAUUCUUCAGACUAUAGAAGGAGCUUCCAGUUGAAUUCACCAGUGGACAAAAUGAGGAAAACAGGUGAACAAGCUUUUUCUGUAUUUACAUACAAAGUCAGAUCAGUUAUGGGACAAUAGUAUUGAAUAGAUUUCAGCUUUAUGCUGGAGUAACUGGCAUGUGAGCAAACUGUGUUGGCGUGGGGGUGGAGGGGUGAGGUGGGCGCUAAGCCUUUUUUUAAGAUUUUUCAGGUACCCCUCACUAAAGGCACCGAAGGCUUAAAGUAGGACAACCAUGGAGCCUUCCUGUGGCAGGAGAGACAACAAAGCGCUAUUAUCCUAAGGUCAAGAGAAGUGUCAGCCUCACCUGAUUUUUAUUAGUAAUGAGGACUUGCCUCAACUCCCUCUUUCUGGAGUGAAGCAUCCGAAGGAAUGCUUGAAGUACCCCUGGGCUUCUCUUAACAUUUAAGCAAGCUGUUUUUAUAGCAGCUCUUAAUAAUAAAGCCCAAAUCUCAAGCGGUGCUUGAAGGGGAGGGAAAGGGGGAAAGCGGGCAACCACUUUUCCCUAGCUUUUCCAGAAGCCUGUUAAAAGCAAGGUCUCCCCACAAGCAACUUCUCUGCCACAUCGCCACCCCGUGCCUUUUGAUCUAGCACAGACCCUUCACCCCUCACCUCGAUGCAGCCAGUAGCUUGGAUCCUUGUGGGCAUGAUCCAUAAUCGGUUUCAAGGUAACGAUGGUGUCGAGGUCUUUGGUGGGUUGAACUAUGUUAGAAAAGGCCAUUAAUUUGCCUGCAAAUUGUUAACAGAAGGGUAUUAAAACCACAGCUAAGUAGCUCUAUUAUAAUACUUAUCCAGUGACUAAAACCAACUUAAACCAGUAAGUGGAGAAAUAACAUGUUCAAGAACUGUAAUGCUGGGUGGGAACAUGUAACUUGUAGACUGGAGAAGAUAGGCAUUUGAGUGGCUGAGAGGGCUUUUGGGUGGGAAUGCAAAAAUUCUCUGCUAAGACUUUUUCAGGUGAACAUAACAGACUUGGCCAAGCUAGCAUCUUAGCGGAAGCUGAUCUCCAAUGCUCUUCAGUAGGGUCAUGAAGGUUUUUCUUUUCCUGAGAAAACAACACGUAUUGUUUUCUCAGGUUUUGCUUUUUGGCCUUUUUCUAGCUUAAAAAAAAAAAAAGCAAAAGAUGCUGGUGGUUGGCACUCCUGGUUUCCAGGACGGGGUUCAAAUCCCUGCGGCGUCUUUGCUUUGACUACUAAUCUGUCUUCAGGACUCUUUCUGUAUUUCUCCUUUUCUCUGCAGGUGCUAGUUCUUGGAGUUUUGGGGAGGUGGGAGGUAACAGCACAAUAUCUUUGAACUAUAUACAUCCUUGAUGUAUAAUUUGUCAGGAGCUUGACUUGAUUGUAUAUUCAUAUUUACACGAGAACCUAAUAUAACUGCCUUGUCUUUUUCAGGUAAUAGCCUGCAGCUGGUGUUUUGAGAAGCCCUACUGCUGAAAACUUAACAAUUUUGUGUAAUAAAAAUGGAGAAGCUCUAAAUUGUUGUGGUUCUUUUGUGAAUAAAAAAAUCUUGAUUGGGGAAAAAA hsa-mir-101-3p hsa-miR-101-3p mirna micro rna micro RNA micro-RNA micro-rna mirna miRNA human Homo sapiens Human UACAGUACUGUGAUAACUGAA malat1-mir101 3p-1 4 8 regulator regulator modulator regulator neutral component neutral component over-expressed over expressed level over-expressed living cell living cell engineered engineered region renilla luciferase renilla luciferase protein tag renilla luciferase certain certain sequence position certain certain certain sequence position certain r.6650_6658delinstcatgaca mutation decreasing mutation decreasing interaction hotspot hotspot mutation decreasing certain certain sequence position certain certain certain sequence position certain CAGUACUGU TCATGAC 9 regulator target regulator target regulator target modulator target neutral component neutral component over-expressed over expressed level over-expressed living cell living cell engineered engineered synthetic construct synthetic construct physical association physical association Fig3A,B mir101 3p-mrna_mcl1-1 1 6 regulator target regulator target regulator target modulator target neutral component neutral component over-expressed over expressed level over-expressed living cell living cell engineered engineered region renilla luciferase renilla luciferase protein tag renilla luciferase undetermined undetermined sequence position undetermined undetermined undetermined sequence position undetermined r.1722_1729delinstcatgaca mutation decreasing mutation decreasing interaction hotspot hotspot mutation decreasing certain certain sequence position certain certain certain sequence position certain AGTACTGT TCATGACA 9 predetermined predetermined participant predetermined tag luciferase tag visualisation by luciferase assay tag luciferase regulator regulator modulator regulator neutral component neutral component over-expressed over expressed level over-expressed living cell living cell engineered engineered synthetic construct synthetic construct physical association physical association Fig5A,C malat1-mir101 3p-2 2 7 unspecified role unspecified role bait bait living cell living cell native native 9 unspecified role unspecified role prey prey living cell living cell native native 8 unspecified role unspecified role prey prey living cell living cell native native association association FIG3E ago2-malat1-1 5 7 unspecified role unspecified role bait bait living cell living cell native native 9 unspecified role unspecified role prey prey living cell living cell native native 8 unspecified role unspecified role prey prey living cell living cell native native association association FIG3E hsa_mir_101 3p-mrna_mcl1-1 3 6 regulator target regulator target regulator target modulator target neutral component neutral component over-expressed over expressed level over-expressed living cell living cell engineered engineered region renilla luciferase renilla luciferase protein tag renilla luciferase undetermined undetermined sequence position undetermined undetermined undetermined sequence position undetermined r.1722_1729delinstcatgaca mutation decreasing mutation decreasing interaction hotspot hotspot mutation decreasing certain certain sequence position certain certain certain sequence position certain AGTACTGT TCATGACA 9 predetermined predetermined participant predetermined tag luciferase tag visualisation by luciferase assay tag luciferase regulator regulator modulator regulator neutral component neutral component over-expressed over expressed level over-expressed living cell living cell engineered engineered synthetic construct synthetic construct physical association physical association Fig5A,C